Non Small Cell Lung Cancer

Often during starting of treatment with locally advanced or metastatic NSCLC  with EGFR activating mutations and switch maintenance treatment in patients, Tarceva is indicated by Oncologists.  In case of one failure of prior chemotherapy regimen,Tarceva is generally prescribed for locally advanced or metastatic NSCLC in the suffering patients. While opting Tarceva, many factors linked to prolonged survival factor should be taken care of. Generally, Patients having Epidermal Growth Factor Receptor (EGFR)-IHC negative tumours, survival benefit or other clinically relevant effects of the treatment is rarely seen.